The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Trends Update — Comparative Effectiveness and Personalized Medicine: Study by CAMH in Toronto will Integrate Genetics, PET Brain Imaging and Pharmacology

CAMH logoToronto’s Centre for Addiction and Mental Health (CAMH) will use a $2.8 million grant from the Canada Foundation for Innovation, along with expected Ontario matching funds, for their ambitious neuroIMAGENE initiative.  The neuroIMAGENE program aims

“to combine the power of genetics and sophisticated brain imaging to personalize treatment … for common psychiatric conditions like major depression, bipolar disorder, schizophrenia, as well as addictions.”

Specifically, CAMH will compare DNA characteristics across 18 different psychiatric conditions and integrate that data with PET scans showing individuals’ neurochemical changes induced by drug therapies. The idea is to create tools to identify the medication that will work best for each individual’s brain chemistry and genotype,

“helping to avoid trial-and-error prescribing, treatment failure, relapse, and serious side effects.”

Bookmark and Share

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


Get every new post delivered to your Inbox.

Join 128 other followers